CytomX Therapeutics Inc (CTMX)
1.07
-0.02
(-1.83%)
USD |
NASDAQ |
Dec 24, 16:00
CytomX Therapeutics Cash from Financing (Quarterly): 0.00 for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Spero Therapeutics Inc | 0.00 |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
| iBio Inc | -0.162M |
| Theriva Biologics Inc | 3.716M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.73M |
| Cash from Investing (Quarterly) | 18.17M |
| Free Cash Flow | -88.78M |
| Free Cash Flow Per Share (Quarterly) | -0.2435 |
| Free Cash Flow to Equity (Quarterly) | -20.75M |
| Free Cash Flow to Firm (Quarterly) | -20.75M |
| Free Cash Flow Yield | -99.29% |